Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 14;45(6):610-614.
doi: 10.3760/cma.j.cn121090-20230912-00113.

[Research progress of tumor-infiltrating lymphocytes in malignant hematological diseases]

[Article in Chinese]
R B Zheng  1 , Y Xiao  1
Affiliations
Review

[Research progress of tumor-infiltrating lymphocytes in malignant hematological diseases]

[Article in Chinese]
R B Zheng et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

In recent years, immunotherapy has been progressing rapidly in tumor treatment, among which, adoptive immunotherapy of immunologically active cells has also gained increasing attention in the treatment of malignant hematological diseases. Tumor-infiltrating lymphocytes are a heterogeneous class of T-cell-based lymphocytes with high heterogeneity. As an important component of the tumor microenvironment, TILs are crucial in the development of malignant tumors. TILs are a new type of immunoreactive cells discovered after lymphokine-activated killer cells, which can show high specificity and efficacy without the need for large amounts of interleukin-2. Tumor immunotherapy with TILs has shown encouraging results and is valuable in determining patient prognosis. In this paper, we review the composition and characteristics of TILs and their progress in malignant hematologic diseases.

近年来，免疫疗法在肿瘤治疗中进展迅速，其中免疫活性细胞的过继免疫治疗在恶性血液系统疾病的治疗中也越来越受到重视。肿瘤浸润性淋巴细胞（tumor-infiltrating lymphocyte，TIL）是一类以T细胞为主的异型淋巴细胞，具有高度异质性。作为肿瘤微环境的重要组成部分，TIL在恶性肿瘤的发生发展中至关重要。TIL是继淋巴因子激活杀伤细胞之后发现的一种新型免疫活性细胞，在不需要大量IL-2诱导的情况下即可展现出强特异性和有效性。本文就TIL的组成、特点和其在恶性血液系统疾病中的研究进展等进行综述。.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Kumar A, Watkins R, Vilgelm AE. Cell Therapy with TILs: Training and Taming T Cells to Fight Cancer[J] Front Immunol. 2021;12:690499. doi: 10.3389/fimmu.2021.690499. - DOI - PMC - PubMed
    1. Paijens ST, Vledder A, de Bruyn M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era[J] Cell Mol Immunol. 2021;18(4):842–859. doi: 10.1038/s41423-020-00565-9. - DOI - PMC - PubMed
    1. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients[J] J Immunother. 2003;26(4):332–342. doi: 10.1097/00002371-200307000-00005. - DOI - PMC - PubMed
    1. Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology[J] Int J Clin Oncol. 2010;15(6):544–551. doi: 10.1007/s10147-010-0130-1. - DOI - PubMed
    1. Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J] Br J Cancer. 2015;112(9):1501–1509. doi: 10.1038/bjc.2015.101. - DOI - PMC - PubMed

MeSH terms